Sana Biotechnology, Inc.
SANA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.1B
$3.85
▼ -1.79%
P/E
-5.13
Mkt Cap
$1.1B
52-Wk Range
$2.61–$6.55
52-Week Range
$2.61 - $6.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 28.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ex vivo and in vivo cell engineering platforms enabling broad therapeutic applications
- Diversified pipeline spanning oncology, hematology, metabolic, and neurological indications reducing development risk
- Allogeneic cell therapy approach (SC291) offering potential off-the-shelf manufacturing advantages over autologous competitors
- Multiple clinical-stage programs providing multiple value inflection points and revenue opportunities
Bear Case
1 risk
- High volatility (beta 2.1). Larger-than-normal price swings expected.
Growth
Stable outlook
Emerging player in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+43.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SANA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 10, 2026
Reported EPS of -$0.13 vs -$0.15 consensus (+11.5% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · $7.00 · Apr 14, 2026
vs Industry
How SANA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related